884495-39-0

Basic information

• Product Name: 5-BROMO-2-METHOXY-3-CYANOPYRIDINE
• Synonyms: 5-BROMO-2-METHOXY-3-CYANOPYRIDINE;5-BROMO-2-METHOXY-3-AMINOPYRIDINE;5-Bromo-2-methoxypyridin-3-amine;5-BroMo-2-Methoxy-3-aMino...;3-PyridinaMine,5-broMo-2-Methoxy-;5-BroMo-2-(Methyloxy)-3-pyridinaMine;5-Bromo-2-methoxypyridin-3-amine, 3-Amino-5-bromopyridin-2-yl methyl ether;3-Amino-5-bromopyridin-2-yl methyl ether
• CAS NO: 884495-39-0
• Molecular Formula: C₆H₇BrN₂O
• Molecular Weight: 203.04
• Product Categories: Pyridine;Heterocycle-Pyridine series
• Mol File: 884495-39-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 53-55℃
• Boiling Point: 284.5 °C at 760 mmHg
• Flash Point: 125.9 °C
• Appearance: /
• Density: 1.622 g/cm³
• Vapor Pressure: 0.00296mmHg at 25°C
• Refractive Index: 1.602
• Storage Temp.: Room temperature.
• PKA: 1.98±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 5-BROMO-2-METHOXY-3-CYANOPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHOXY-3-CYANOPYRIDINE(884495-39-0)
• EPA Substance Registry System: 5-BROMO-2-METHOXY-3-CYANOPYRIDINE(884495-39-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41-43
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 884495-39-0(Hazardous Substances Data)

Usage

Uses

3-Amino-5-bromo-2-methoxypyridine is used as pharmaceutical intermediate.

InChI:InChI=1/C6H7BrN2O/c1-10-6-5(8)2-4(7)3-9-6/h2-3H,8H2,1H3

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 

Downstream Products

• 1083326-73-1 N-(2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1246373-16-9 2,4-difluoro-N-[2-methoxy-5-(5-iodoimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide 
• 1246373-17-0 2,4-difluoro-N-[2-methoxy-5-(5-pyridazin-4-yl-imidazo[2,1-b][1,3,4]thiadiazol-2-yl)-pyridin-3-yl]-benzenesulfonamide 
• 1360537-69-4 N-(5-bromo-2-methoxypyridin-3-yl)-4-fluoro-2-nitrobenzenesulfonamide 
• 1360537-70-7 N-(5-bromo-2-methoxypyridin-3-yl)-2-fluoro-4-nitrobenzenesulfonamide 
• 1086062-66-9 GS⁽²⁶⁴⁾K₂₁₅₈ 
• 1360537-71-8 4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-2-nitrobenzenesulfonamide 
• 1360537-72-9 2-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)-4-nitrobenzenesulfonamide 
• 1360537-73-0 2,4-difluoro-N-(2-hydroxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-75-2 2-[⁽¹⁸⁾F]fluoro-4-fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1360537-76-3 2-fluoro-4-[⁽¹⁸⁾F]fluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1621718-51-1 2,4-difluoro-N-(5-(3-(3-hydroxyprop-1-yn-1-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1621718-29-3 N-(5-(3-cyanopyrazolo[1,5-a]pyrimidin-5-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1621718-37-3 N-(5-(3-cyanopyrazole[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzene sulfonamide 

Relevant articles and documents

Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors

Phosphoinositide 3-kinases (PI3Ks) are regarded as promising targets for treatment of various cancers due to their roles in regulating cell proliferation, differentiation, migration, and survival. Here we report our efforts to develop potent and orally bioavailable PI3K inhibitors for the treatment of cancers. The alkylsulfonamide-containing quinazoline derivatives A1–A18 significantly inhibited PI3Kα, and cell proliferation among HCT-116, MCF-7 and SU-DHL-6 cell lines. The optimal compound A1 displayed potent inhibitory activity against PI3Kα (IC50 = 4.5 nM), PI3Kβ (IC50 = 4.5 nM), PI3Kγ (IC50 = 4.5 nM), PI3Kδ (IC50 = 4.5 nM) and significantly inhibited the growth of HCT-116, MCF-7 and SU-DHL-6 cell lines with IC50 values of 0.82 μM, 0.99 μM and 0.19 μM, respectively. Western blot analysis demonstrated A1 significantly suppressed the phosphorylation of AKTS473 in a dose-dependent manner. Furthermore, A1 could markedly inhibit cancer growth at the dose of 25 mg/kg in nude mouse HCT-116 xenograft model in vivo without causing significant weight loss or toxicity.

Indazole derivatives for use in the treatment of influenza virus infection

The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors

Abstract A novel series of 4-alkynyl-quinoline derivatives were designed, synthesized and biologically evaluated for their PI3Kα inhibitory activities and anti-proliferative effects against two cancer cell lines PC-3 and HCT-116. Most of them showed potent PI3Kα inhibitory activities with IC50 values at low nanomolar level and good to excellent anti-proliferative effects against both cell lines. Among them, compound 15d, the most potent one, was selected for further biological evaluation. As a result, 15d displayed strong inhibitory activity against other class I PI3K isoforms (PI3Kβ, PI3Kγ and PI3Kδ) and mTOR with an acceptable kinase selectivity profile. Moreover, the western blot assay indicated that the phosphorylation of Akt, another downstream effector of PI3K, can be remarkably suppressed by 15d at cellular level. All these experimental results suggested that 15d is a potent PI3K/mTOR dual inhibitor and could serve as a promising lead compound for the development of anticancer agents.